Physicians' Academy for Cardiovascular Education

Agenda Topics ▼On-demand Online-CME Podcasts News ▼Programs Slides ▼About

Anticoagulation ▼Diabetes & CVD ▼Heart Failure ▼Kidney disease & CVD ▼Lipids ▼

SGLT2 inhibition

May 10, 2016

Share this page with your colleagues and friends:

Continue reading:

Anticoagulation

Longer DOAC treatment reduces risk of recurrent VTE with no increased bleeding risk

Literature - Feb. 13, 2023 - Ageno W, et al. - BMJ. 2022

Monotherapy with oral anticoagulant beyond 1 year after PCI as effective and safe as dual therapy in stable AF patients

Literature - Dec. 5, 2022 - Jensen T, et al. - Eur Heart J Cardiovasc Pharmacother. 2022

DOAC vs. standard of care after TAVR: risk of valve thrombosis and clinical outcomes

Literature - Oct. 17, 2022 - Montalescot G, et al. - JACC Cardiovasc Interv. 2022

Diabetes & CVD

Beneficial effects of nonsteroidal MRA on mortality in patients with CKD and T2DM

Literature - Mar. 15, 2023 - Filippatos G, et al. - Eur Heart J Cardiovasc Pharmacother. 2023

Multifaceted intervention improves prescription of therapies in T2DM and ASCVD

News - Mar. 10, 2023

Expanded indication for non-steroidal MRA in EU for broad range of patients with CKD and T2DM

News - Mar. 1, 2023

Heart Failure

Treatment effects of ARNI in HF independent of eGFR decline during run-in phase

Literature - Mar. 20, 2023 - Chatur S, Claggett BL, McCausland FR, et al. - J Am Coll Cardiol. 2023

SGLT2i improves CV outcomes in patients with HFmrEF or HFpEF regardless of kidney function

Literature - Mar. 14, 2023 - Mc Causland FR, et al. - JAMA Cardiol. 2023

SGLT2i improves hemodynamic function in HFpEF

News - Mar. 8, 2023

Kidney disease & CVD

Treatment effects of ARNI in HF independent of eGFR decline during run-in phase

Literature - Mar. 20, 2023 - Chatur S, Claggett BL, McCausland FR, et al. - J Am Coll Cardiol. 2023

Beneficial effects of nonsteroidal MRA on mortality in patients with CKD and T2DM

Literature - Mar. 15, 2023 - Filippatos G, et al. - Eur Heart J Cardiovasc Pharmacother. 2023

SGLT2i improves CV outcomes in patients with HFmrEF or HFpEF regardless of kidney function

Literature - Mar. 14, 2023 - Mc Causland FR, et al. - JAMA Cardiol. 2023

Lipids

Bempedoic acid reduces hs-CRP, but not fibrinogen and IL-6 in patients with residual inflammatory risk

Literature - Mar. 16, 2023 - Ridker PM, et al. - J Clin Lipidol. 2023

Promising results for oral PCSK9i to proceed to phase 3 trials

3' education - Mar. 8, 2023 - Prof. Christie Ballantyne, MD

New oral PCSK9 inhibitor lowers LDL-c in hypercholesterolemia

News - Mar. 8, 2023

© 2006 - 2023 pace-cme.org - About